GenSight Biologics: Pioneer trial on GS030 published in NEJM, visual signals in 6 out of 10 patients
GenSight Biologics and the National Hospital of 15-20 announced on October 8, 2026 the publication, in The New England Journal of Medicine, of the results of the PIONEER trial dedicated to GS030, an optogenetic therapy candidate for retinitis pigmentosa at an advanced stage. The study was designed to assess tolerability. It also reports visual responses measured in a portion of the ten participants, which the authors present as exploratory.
GS030 is the second candidate in the biotech's portfolio, behind GS010, in phase 3 for Leber hereditary optic neuropathy. The publication comes on the same day as the announcement of a capital raise generating net proceeds of approximately 0.95 million euros, fully subscribed by Heights Capital and Invus, two existing shareholders.
No systemic adverse events related to treatment
The primary endpoint of the trial focused on the safety and tolerability of GS030. According to the article, most ocular adverse events were mild or moderate. The only event classified as severe resolved within minutes after instillation of Iopidine.
No systemic adverse events were deemed related to the studied product or intravitreal injection. GS030 combines gene therapy, administered as a single intravitreal injection in one eye, with light-stimulation glasses that activate photosensitive proteins produced in retinal ganglion cells.
PIONEER is a first-in-human, multicenter, open-label study with dose escalation. Three cohorts of three patients each received one of the three doses tested, in the least-sighted eye. Given the safety profile, the Data Safety Monitoring Board (DSMB) approved an extension cohort at the highest dose, in which one patient was enrolled.
Six out of ten patients with improved light sensitivity
The authors emphasize that the study was not designed to establish the efficacy of GS030. However, they highlight several exploratory results. In six of the ten participants, evaluations showed clinically significant improvement in light sensitivity, measured by the full-field stimulus threshold test (FST).
Among the eight participants who completed behavioral testing, four showed positive changes in certain tasks performed with stimulation glasses: detecting, locating or touching objects, or determining bar orientation. High-density EEG recordings, performed on a subset of participants, showed modifications consistent with visual signal transmission to the visual cortex.
These data should be viewed in light of the protocol: ten treated patients, an open-label trial and exploratory efficacy assessments. Professor José-Alain Sahel, co-founder of GenSight Biologics, himself indicated this by estimating that these results "remain exploratory and will need to be confirmed and further explored".
Safety follow-up planned up to five years after injection
Analyses of the primary endpoint focus on safety and tolerability with follow-up extending up to five years after injection. This long-term follow-up is conducted at three centers, in the United Kingdom, France and the United States. GS030 has not received marketing authorization in any country.
The mechanism explains the interest in the program: the therapy makes retinal cells light-sensitive by bypassing destroyed photoreceptors, and its approach is independent of the underlying genetic mutation. Retinitis pigmentosa, linked to mutations in over 100 genes, affects approximately one person in 4,000, or more than 1.5 million people worldwide, and most patients have no approved treatment.
According to the press release, the publication comes a few days after the award of the 2026 Nobel Prize in Physiology or Medicine to Karl Deisseroth, Peter Hegemann and Georg Nagel for their work on light-activated ion channels and optogenetics. Financially, the company reported on September 30, 2026, 6.5 million euros in cash receipts in the first half of 2026 from the paid compassionate use programs of GS010/Lumevoq.
The central element of the publication remains a tolerability trial conducted on ten patients, with no systemic events deemed related to treatment, in which six participants showed an improvement in light sensitivity.
